Explore
Validate
Learn
Western blot
ELISAAntibody data
- Antibody Data
- Antigen structure
- References [7]
- Comments [0]
- Validations
- Western blot [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 13037-1-AP - Provider product page
- Provider
- Proteintech Group
- Proper citation
- Proteintech Cat#13037-1-AP, RRID:AB_10640800
- Product name
- TRIM37 antibody
- Antibody type
- Polyclonal
- Description
- KD/KO validated TRIM37 antibody (Cat. #13037-1-AP) is a rabbit polyclonal antibody that shows reactivity with human, mouse and has been validated for the following applications: IF, IHC, WB,ELISA.
- Reactivity
- Human, Mouse
- Host
- Rabbit
- Conjugate
- Unconjugated
- Isotype
- IgG
- Vial size
- 20ul, 150ul
Submitted references TRIM37 is a primate-specific E3 ligase for Huntingtin and accounts for the striatal degeneration in Huntington's disease.
TRIM37 promotes gallbladder cancer proliferation by activating the Wnt/β-catenin pathway via ubiquitination of Axin1.
TRIM37 exacerbates hepatic ischemia/reperfusion injury by facilitating IKKγ translocation.
Downregulation of BASP1 Promotes Temozolomide Resistance in Gliomas via Epigenetic Activation of the FBXO32/NF-κB/MGMT Axis.
The TRIM37 variants in Mulibrey nanism patients paralyze follicular helper T cell differentiation.
Aerobic glycolysis and tumor progression of hepatocellular carcinoma are mediated by ubiquitin of P53 K48-linked regulated by TRIM37.
Tripartite motif containing protein 37 involves in thrombin stimulated BV-2 microglial cell apoptosis and interleukin 1β release.
Qin Y, Chen L, Zhu W, Song J, Lin J, Li Y, Zhang J, Song X, Xing T, Guo T, Duan X, Zhang Y, Ruan E, Wang Q, Li B, Yang W, Yin P, Yan XX, Li S, Li XJ, Yang S
Science advances 2024 May 17;10(20):eadl2036
Science advances 2024 May 17;10(20):eadl2036
TRIM37 promotes gallbladder cancer proliferation by activating the Wnt/β-catenin pathway via ubiquitination of Axin1.
Xu M, Jiang B, Man Z, Zhu H
Translational oncology 2023 Sep;35:101732
Translational oncology 2023 Sep;35:101732
TRIM37 exacerbates hepatic ischemia/reperfusion injury by facilitating IKKγ translocation.
Yang H, Huang Z, Luo Y, Lei D, Yan P, Shen A, Liu W, Li D, Wu Z
Molecular medicine (Cambridge, Mass.) 2023 May 8;29(1):62
Molecular medicine (Cambridge, Mass.) 2023 May 8;29(1):62
Downregulation of BASP1 Promotes Temozolomide Resistance in Gliomas via Epigenetic Activation of the FBXO32/NF-κB/MGMT Axis.
Liao X, Li Z, Zheng H, Qian W, Zhang S, Chen S, Li X, Tang M, Xu Y, Yu R, Li M, Song L, Li J
Molecular cancer research : MCR 2023 Jul 5;21(7):648-663
Molecular cancer research : MCR 2023 Jul 5;21(7):648-663
The TRIM37 variants in Mulibrey nanism patients paralyze follicular helper T cell differentiation.
Gu W, Zhang J, Li Q, Zhang Y, Lin X, Wu B, Yin Q, Sun J, Lu Y, Sun X, Jia C, Li C, Zhang Y, Wang M, Yin X, Wang S, Xu J, Wang R, Zhu S, Cheng S, Chen S, Liu L, Zhu L, Yan C, Yi C, Li X, Lian Q, Lin G, Ling Z, Ma L, Zhou M, Xiao K, Wei H, Hu R, Zhou W, Ye L, Wang H, Li J, Sun B
Cell discovery 2023 Aug 1;9(1):82
Cell discovery 2023 Aug 1;9(1):82
Aerobic glycolysis and tumor progression of hepatocellular carcinoma are mediated by ubiquitin of P53 K48-linked regulated by TRIM37.
Ge Y, Zhao R, Li B, Xiao B, Zhou L, Zuo S
Experimental cell research 2022 Dec 15;421(2):113377
Experimental cell research 2022 Dec 15;421(2):113377
Tripartite motif containing protein 37 involves in thrombin stimulated BV-2 microglial cell apoptosis and interleukin 1β release.
Han C, Xia X, Jiao S, Li G, Ran Q, Yao S
Biochemical and biophysical research communications 2019 Sep 3;516(4):1252-1257
Biochemical and biophysical research communications 2019 Sep 3;516(4):1252-1257
No comments: Submit comment
Supportive validation
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- The TRIM37 antibody from Proteintech is a rabbit polyclonal antibody to a recombinant protein of human TRIM37. This antibody recognizes human, mouse, rat antigen. The TRIM37 antibody has been validated for the following applications: ELISA, WB analysis.
